Mr. Caldwell represented Medtronic in defense of a patent infringement lawsuit pending in the District of New Jersey where local companies Wyeth and Cordis accused Medtronic of infringing patents pertaining to the use of the drug rapamycin (now commercially known as sirolimus) to treat restenosis—re-narrowing of an artery following an angioplasty procedure. The district court granted Medtronic’s motion for summary judgment invalidating the asserted patents.